YK Bioventures Opportunities GP I, LLC - 11 Dec 2024 Form 4 Insider Report for CERO THERAPEUTICS HOLDINGS, INC. (CERO)

Role
10%+ Owner
Signature
YK Bioventures Opportunities GP I, LLC, By /s/ Gary K. Yeung, Managing Partner
Issuer symbol
CERO
Transactions as of
11 Dec 2024
Net transactions value
-$400,456
Form type
4
Filing time
13 Dec 2024, 18:41:13 UTC
Previous filing
10 Dec 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CERO Common Stock Sale $107,504 -1,343,801 -7.1% $0.0800 17,618,618 11 Dec 2024 By YK Bioventures Opportunities Fund I, L.P. F1
transaction CERO Common Stock Sale $113,018 -1,614,541 -9.2% $0.0700 16,004,077 12 Dec 2024 By YK Bioventures Opportunities Fund I, L.P. F1
transaction CERO Common Stock Sale $179,934 -2,998,908 -19% $0.0600 13,005,169 13 Dec 2024 By YK Bioventures Opportunities Fund I, L.P. F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

YK Bioventures Opportunities GP I, LLC is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may continue.

Explanation of Responses:

Id Content
F1 Securities are held directly by YK Bioventures Opportunities Fund I, L.P. (f/k/a YK Bioventures, LLC) ("YK Opps I"). YK Bioventures Opportunities GP I, LLC ("YK Opps I GP") is the general partner of YK Opps I and may be deemed to beneficially own the shares held by YK Opps I. Mitchell W. Kossar and Gary K. Yeung are managing partners of YK Opps I GP, and may be deemed to share voting and investment power over the shares held by YK Opps I. Each of YK Opps I GP and Messrs. Kossar and Yeung disclaims beneficial ownership of these shares except to the extent of its or his respective pecuniary interest therein.